CORT
CORCEPT THERAPEUTICS INC
NASDAQ · Healthcare · Biotechnology · US
$89.02
−17.19%Oct 20, 2026, 20:00 UTC
The American Diabetes Association and the European Association for the Study of Diabetes published their 2026 consensus report on the management of type 2 diabetes, which recommends screening for hypercortisolism in patients with difficult-to-control type 2 diabetes.
Source:Sep 23, 2026, 12:17 UTC
Sean Maduck, President of Corcept Endocrinology at Corcept Therapeutics, is retiring effective October 1, 2026, and will provide consulting services at $57,000 per month through September 30, 2027.
Source:Sep 23, 2026, 12:17 UTC
Justin Gunn was appointed President, Endocrinology at Corcept Therapeutics effective October 1, 2026.
Sep 18, 2026, 12:00 UTC
The European Medicines Agency's Committee for Medicinal Products for Human Use recommended that the European Commission approve Corcept Therapeutics' relacorilant (Lifyorli) for EU marketing authorization.
Source:Sep 16, 2026, 15:45 UTC
Corcept Therapeutics' Korlym sales rose 6.2% in the first half of 2026 on growing demand, while the launch of Lifyorli offers a path to diversify revenues.
Source:Sep 16, 2026, 10:23 UTC
Institutions continued buying Corcept Therapeutics shares in large volumes, lifting the stock 1,016% since 2017 and putting it on the cusp of joining the S&P MidCap 400 index.
Source:Sep 4, 2026, 21:50 UTC
Dow Jones Indices announced changes to the S&P 600 index, adding ten companies and removing ten others, effective before the open on September 21, 2026, as part of the quarterly rebalance.
Source:Sep 4, 2026, 21:18 UTC
S&P Dow Jones Indices announced the inclusion of HubSpot, AGNC, Corcept, and Brinker into the S&P MidCap 400 index.
Source:Jul 31, 2026, 15:34 UTC
Corcept Therapeutics launched LIFYORLI, which generated $47.6 million in its first full quarter.
Source:Jul 29, 2026, 20:05 UTC
Corcept Therapeutics reported its financial results for the second quarter ended June 30, 2026.
Jun 22, 2026, 21:00 UTC
Fred Alger Management, LLC announced the quarterly rebalancing of the Alger Russell Innovation Index, effective after the close of trading on June 26, 2026, with additions and deletions of several companies.
Source:Jun 17, 2026, 20:28 UTC
Corcept Therapeutics resubmitted its New Drug Application to the FDA for relacorilant as a treatment for Cushing's syndrome.
Source: